Applied Therapeutics (NASDAQ:APLT) Releases Earnings Results

Key Points

• Applied Therapeutics reported a quarterly **EPS** of ($0.15), exceeding analysts' expectations of ($0.17) by **$0.02**.
• The company's stock traded up to **$0.45** with an average target price of **$6.10** and a current rating of **"Hold"** from analysts.
• A hedge fund recently acquired a **new stake** in Applied Therapeutics, purchasing **572,311 shares** valued at approximately **$280,000**.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02, Zacks reports.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $0.45. 963,036 shares of the company were exchanged, compared to its average volume of 2,671,608. The firm has a 50 day simple moving average of $0.40 and a 200-day simple moving average of $0.45. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62. The firm has a market cap of $63.92 million, a P/E ratio of -1.05 and a beta of 1.97.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Wall Street Zen upgraded Applied Therapeutics to a "sell" rating in a research report on Saturday, July 26th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $1.50 price objective on shares of Applied Therapeutics in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Applied Therapeutics presently has an average rating of "Hold" and an average target price of $6.10.

Hedge Funds Weigh In On Applied Therapeutics

A hedge fund recently bought a new stake in Applied Therapeutics stock. AQR Capital Management LLC acquired a new stake in Applied Therapeutics Inc. (NASDAQ:APLT - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 572,311 shares of the company's stock, valued at approximately $280,000. AQR Capital Management LLC owned about 0.40% of Applied Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.